Atlas Trials

Refractory Transformed Chronic Lymphocytic Leukemia

12 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Transformed Chronic Lymphocytic Leukemia

RecordFirmDate
Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia (NCT07166419)Ohio State University Comprehensive Cancer Center2026-01-14
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation (NCT06735664)City of Hope Medical Center2025-08-14
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies (NCT06343376)Roswell Park Cancer Institute2024-11-26
Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT06247540)Northwestern University2024-03-29
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies (NCT06191887)Mayo Clinic2024-03-18
Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (NCT05672251)City of Hope Medical Center2024-01-02
Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome (NCT05873712)Aseel Alsouqi2023-07-28
Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation (NCT05672173)City of Hope Medical Center2023-06-02
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies (NCT04892277)Mayo Clinic2022-10-03
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088)Sumithira Vasu2022-06-30
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729)Fred Hutchinson Cancer Center2017-12-05
Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome (NCT02846623)M.D. Anderson Cancer Center2017-01-31

Track Refractory Transformed Chronic Lymphocytic Leukemia automatically

Every clearance here is in the API, with alerts when new ones post.